Literature DB >> 32340706

Treat to Target in Axial Spondyloarthritis: Pros, Cons, and Future Directions.

Jean W Liew1, Maureen Dubreuil2.   

Abstract

Treat to target describes a management paradigm that involves choosing a clinically relevant target, assessment with validated measures at a prespecified frequency, and a change in therapy if the target is not met. Although guidelines recommend treating to target in axial spondyloarthritis (axSpA), ideal methods to reach this target remain controversial. This review focuses on background for a treat-to-target strategy in axSpA. Potential targets of treatment, association of targets with outcomes, evidence of treatment impact on outcomes, and how treat to target has been incorporated into treatment guidelines are discussed. Treat-to-target trials and the research agenda for studies in axSpA are discussed. Published by Elsevier Inc.

Entities:  

Keywords:  Ankylosing spondylitis; Axial spondyloarthritis; Disease activity; Treat to target

Year:  2020        PMID： 32340706      PMCID： PMC8106802          DOI： 10.1016/j.rdc.2020.01.011

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  82 in total

1.  Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment.

Authors:  L C Coates; J Fransen; P S Helliwell
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

2.  Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis.

Authors:  Uta Kiltz; Désirée van der Heijde; Annelies Boonen; Nurullah Akkoc; Wilson Bautista-Molano; Ruben Burgos-Vargas; James Cheng-Chung Wei; Praveena Chiowchanwisawakit; Maxime Dougados; M Tuncay Duruoz; Bassel Kamal Elzorkany; Inna Gaydukova; Lianne S Gensler; Michele Gilio; Simeon Grazio; Jieruo Gu; Robert D Inman; Tae-Jong Kim; Victoria Navarro-Compan; Helena Marzo-Ortega; Salih Ozgocmen; Fernando Pimentel Dos Santos; Michael Schirmer; Simon Stebbings; Filip E Van den Bosch; Astrid van Tubergen; Juergen Braun
Journal:  Ann Rheum Dis       Date:  2018-06-01       Impact factor: 19.103

Review 3.  Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: A systematic review and meta-analysis.

Authors:  Julio Ramírez; Juan Carlos Nieto-González; Rafael Curbelo Rodríguez; Santos Castañeda; Loreto Carmona
Journal:  Semin Arthritis Rheum       Date:  2017-12-07       Impact factor: 5.532

4.  Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis.

Authors:  Denis Poddubnyy; Hildrun Haibel; Joachim Listing; Elisabeth Märker-Hermann; Henning Zeidler; Jürgen Braun; Joachim Sieper; Martin Rudwaleit
Journal:  Arthritis Rheum       Date:  2012-05

5.  Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis.

Authors:  Pedro Machado; Robert Landewé; Jürgen Braun; Kay-Geert A Hermann; Daniel Baker; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-24       Impact factor: 19.103

6.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.

Authors:  S Garrett; T Jenkinson; L G Kennedy; H Whitelock; P Gaisford; A Calin
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

7.  Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort.

Authors:  Victoria Navarro-Compán; Sofia Ramiro; Robert Landewé; Maxime Dougados; Corinne Miceli-Richard; Pascal Richette; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2015-09-24       Impact factor: 19.103

8.  Cardiovascular events in ankylosing spondylitis: a 2018 meta-analysis.

Authors:  Sylvain Mathieu; Martin Soubrier
Journal:  Ann Rheum Dis       Date:  2018-03-09       Impact factor: 19.103

9.  2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Authors:  Michael M Ward; Atul Deodhar; Lianne S Gensler; Maureen Dubreuil; David Yu; Muhammad Asim Khan; Nigil Haroon; David Borenstein; Runsheng Wang; Ann Biehl; Meika A Fang; Grant Louie; Vikas Majithia; Bernard Ng; Rosemary Bigham; Michael Pianin; Amit Aakash Shah; Nancy Sullivan; Marat Turgunbaev; Jeff Oristaglio; Amy Turner; Walter P Maksymowych; Liron Caplan
Journal:  Arthritis Rheumatol       Date:  2019-08-22       Impact factor: 15.483

10.  TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort.

Authors:  Christoph Molnar; Almut Scherer; Xenofon Baraliakos; Manouk de Hooge; Raphael Micheroli; Pascale Exer; Rudolf O Kissling; Giorgio Tamborrini; Lukas M Wildi; Michael J Nissen; Pascal Zufferey; Jürg Bernhard; Ulrich Weber; Robert B M Landewé; Désirée van der Heijde; Adrian Ciurea
Journal:  Ann Rheum Dis       Date:  2017-09-22       Impact factor: 19.103
View more
  2 in total

1.  Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study.

Authors:  Atul A Deodhar; Natalie J Shiff; Cinty Gong; Elizabeth C Hsia; Kim Hung Lo; Lilliane Kim; Stephen Xu; John D Reveille
Journal:  J Clin Rheumatol       Date:  2022-06-01       Impact factor: 3.902

2.  Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort.

Authors:  Laura Pina Vegas; Emilie Sbidian; Daniel Wendling; Philippe Goupille; Salah Ferkal; Philippe Le Corvoisier; Bijan Ghaleh; Alain Luciani; Pascal Claudepierre
Journal:  Rheumatology (Oxford)       Date:  2022-04-11       Impact factor: 7.580
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.